title: Vascular brachytherapy and the strontium90 vascular brachytherapy system.
abstract: Restenosis remains a vexing problem in patients undergoing percutaneous coronary interventions (PCI). This phenomenon is related to a combination of events, including elastic recoil, negative remodeling and fibrointimal tissue proliferation. While stenting (bare metal and drug eluting) has made a dramatic impact in preventing recoil and remodeling, restenosis still occurs. Once restenosis occurs, it presents its own set of challenges due to the excess tissue proliferation. Major predicators of restenosis include diabetes, small stent diameter and long stented lesions. Vascular brachytherapy is the only proven therapy associated with a significant reduction in angiographic restenosis and the need for target vessel revascularization for the treatment of in-stent restenosis.
authors.affiliation: Swedish Medical Center, Cardiovascular Research, 1221 Madison Avenue, Suite 1020, Seattle, WA 98104, USA. markreisman@earthlink.net
authors.forename: Mark
authors.initials: M
authors.lastname: Reisman
authors.forename: William A
authors.initials: WA
authors.lastname: Gray
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D001918:Brachytherapy / Q000379:methods*; D023903:Coronary Restenosis / Q000209:etiology / Q000532:radiotherapy*; D006801:Humans; D018579:Patient Selection; D015607:Stents / Q000009:adverse effects*; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
chemical_list: D013326:Strontium Radioisotopes